Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2005

01-05-2005 | Poster presentation

6-(1-oxobutyl)-5,8-dimetoxy-1,4-naphthoquinone inhibits the growth of MCF-7 cells via inhibition of angiogenesis and hypoxia inducible factor alpha

Author: S-H Kim

Published in: Breast Cancer Research | Special Issue 1/2005

Login to get access

Excerpt

Hypoxia induces the transcription of various genes that are involved in angiogenesis and anaerobic metabolism necessary for the growth of tumor cells. Hypoxia-inducible factor (HIF)-1α regulates genes that are involved in the response to hypoxia and promotes neoangiogenesis in cancer. Thus, 6-(1-oxobutyl)-5,8-dimetoxy-1,4-naphthoquinone (OXO) was synthesized, to develop an anticancer agent with antiangiogenic activity in hypoxic cancer cells. …
Metadata
Title
6-(1-oxobutyl)-5,8-dimetoxy-1,4-naphthoquinone inhibits the growth of MCF-7 cells via inhibition of angiogenesis and hypoxia inducible factor alpha
Author
S-H Kim
Publication date
01-05-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1239

Other articles of this Special Issue 1/2005

Breast Cancer Research 1/2005 Go to the issue

Poster presentation

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

Oral presentation

Radiotherapy in early stage invasive breast cancer: current tendencies

Oral presentation

Chemoprevention: beyond tamoxifen

Oral presentation

Neoadjuvant treatment: the MD Anderson experience

Oral presentation

Present situation and future of genetic profiling for prognosis and treatment

Oral presentation

Primary chemotherapy for operable breast cancer: the NSABP experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits